Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET
Company Participants
Cedric Francois – Co-Founder and CEO
Caroline Baumal – Chief Medical Officer
David Acheson – EVP, Commercial
Tim Sullivan – CFO
Meredith Kaya – SVP, IR and Strategic Finance
Conference Call Participants
Jon Miller – Evercore ISI
Tazeen Ahmad – Bank of America Securities
Malcolm Kuno – J.P. Morgan
Salveen Richter – Goldman Sachs
Yigal Nochomovitz – Citigroup
Colleen Cusi – Robert W. Baird
Phil Nadeau – TD Cowen
Katherine Wang – Jefferies
Ellie Merle – UBS
Annabel Samimy – Stifel
Douglas Tsao – H. C. Wainwright
Joseph Springer – Needham & Company
Lachlan Hanbury-Brown – William Blair
Ryan Deschner – Raymond James
Derek Acula – Wells Fargo
Operator
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and full-year 2024 earnings conference call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the call over to Meredith Kaya, Senior Vice President, Investor Relations, and Strategic Finance. Please go ahead.
Meredith Kaya
Good morning, and thank you for joining us to discuss Apellis’ fourth quarter and full-year 2024 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Executive Vice President of Commercial, David Acheson; Chief Medical Officer, Dr. Caroline Baumal; and Chief Financial Officer, Tim Sullivan.
Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional details.
Now, I’ll turn the call over to Cedric.
Cedric